Ocrevus denied by insurance? Appeal and win.
A denial of Ocrevus is rarely the final word. It is usually the start of a process, and the most common reasons it is denied are also the most fixable: step therapy that asks you to fail other disease-modifying therapies first, missing prior-authorization documentation, or site-of-care restrictions on where the infusion is given. When the appeal pairs a confirmed MS diagnosis with the required baseline screening and a clear letter of medical necessity, these denials are frequently overturned.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Ocrevus (ocrelizumab) is FDA approved to treat relapsing forms of multiple sclerosis, which includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It is also approved for primary progressive MS and remains the only therapy FDA approved for that form of the disease. The label has been expanded to include children ages 10 and older with relapsing-remitting MS. Ocrevus is given as an intravenous infusion, with an initial dose split into two 300 mg infusions two weeks apart, followed by a single 600 mg infusion every six months.
Why Ocrevus gets denied
- Step therapy: the plan requires documented trial and failure or intolerance of one or more preferred disease-modifying therapies before it will cover Ocrevus.
- Prior authorization criteria not met on paper: the MS subtype, neurologist involvement, or required baseline labs are not clearly documented in the submission.
- Missing baseline hepatitis B screening (HBsAg and anti-HBc), which the label requires before starting, since B-cell depletion can reactivate the virus.
- Site-of-care restriction: the plan will not cover the infusion at a hospital outpatient center and directs it to a physician office, infusion suite, or home setting.
What a winning appeal includes
- A confirmed MS diagnosis with the specific subtype and the ICD-10 code (for example G35), plus MRI and clinical findings that establish active or progressive disease.
- A documented history of prior disease-modifying therapies tried, with the dates, the reason each was stopped, and any intolerance or contraindication that justifies skipping step therapy.
- Point-by-point mapping of the patient's chart to the plan's own published Ocrevus coverage criteria, so each required element is visibly satisfied.
- A neurologist letter of medical necessity attached to baseline screening results, including hepatitis B testing and a management plan if any result is positive.
How we approach the appeal
First identify which kind of denial you received, because the path differs. A step-therapy or criteria denial is answered with a prior-authorization appeal or step-therapy exception that quotes the plan's own medical policy language and shows, line by line, that each requirement is met or medically inappropriate to require. If the issue is formulary tier or site of care, request a formulary or site-of-care exception with the neurologist documenting why the alternative is unsafe or ineffective for this patient, and preserve your right to external review if the internal appeal is upheld.
Ocrevus appeal letter template
Copy this Ocrevus appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Anti-CD20 monoclonal antibody denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Ocrevus denial I am appealing the denial of Ocrevus (ocrelizumab). I request that the denial be overturned and Ocrevus approved. 1. The denial. [Insurer] denied Ocrevus stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Ocrevus is medically necessary for my condition. First identify which kind of denial you received, because the path differs. A step-therapy or criteria denial is answered with a prior-authorization appeal or step-therapy exception that quotes the plan's own medical policy language and shows, line by line, that each requirement is met or medically inappropriate to require. If the issue is formulary tier or site of care, request a formulary or site-of-care exception with the neurologist documenting why the alternative is unsafe or ineffective for this patient, and preserve your right to external review if the internal appeal is upheld. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Ocrevus within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Ocrevus denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
My plan says I have to fail another MS drug before Ocrevus. Can I appeal that?
Yes. This is a step-therapy requirement, and it can be challenged with a step-therapy exception. If you have already tried and failed or could not tolerate a required therapy, document the drug names, dates, and reasons it was stopped. If a required drug is contraindicated or medically inappropriate for you, your neurologist can state that in writing, and many plans will waive the step when that justification is clear.
Does Ocrevus get billed under my pharmacy benefit or my medical benefit?
Because Ocrevus is given as an infusion by a healthcare professional, it is usually covered under the medical benefit and billed with HCPCS code J2350, not through your pharmacy plan. This matters for appeals, because the prior-authorization rules, the appeal forms, and any site-of-care policy come from the medical side of your plan rather than the pharmacy side.
I was approved before. Why was my renewal denied?
Reauthorization denials usually come from missing documentation of continued benefit rather than a change in the rules. Plans typically want to see that you are stable or improving on therapy and that there is no untreated safety concern. Submitting updated neurology notes, current MRI or clinical status, and confirmation that monitoring is up to date generally resolves a renewal denial on appeal.
Ocrevus denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.